The 2017 WHO classification of pituitary adenoma: overview and comments

被引：78
作者：
Inoshita, Naoko [1 ,3 ]
Nishioka, Hiroshi [2 ,3 ]
机构：
[1] Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan
[2] Toranomon Gen Hosp, Dept Hypothalam & Pituitary Surg, Tokyo, Japan
[3] Okinaka Mem Inst Med Res, Tokyo, Japan
来源：
BRAIN TUMOR PATHOLOGY | 2018年 / 35卷 / 02期
关键词：
Pituitary adenoma; WHO classification; Pathology; HEALTH-ORGANIZATION CLASSIFICATION; TUMORS; DIAGNOSIS;
D O I：
10.1007/s10014-018-0314-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The fourth edition of the World Health Organization classification of endocrine tumors has been recently published. There are two critical changes to the classification for pituitary adenomas in this edition. One is that the term "atypical adenoma," which was characterized based on highly proliferative properties to predict adenomas that carry a poor prognosis, was completely eliminated due to the lack of definitive evidence. The other change is the introduction of more precise cell lineage-based classification of pituitary adenoma that is defined based on lineage-specific transcription factors and hormones produced. Accordingly, null cell adenomas have been re-defined as those that show completely negative immunostaining either for hormones or for adenohypophyseal transcription factors. In this review, we summarized these changes in the WHO classification and discussed topics that are relevant to the diagnosis of actual cases: immunohistochemical study for pituitary endocrine tumors, predictive markers for malignant potential, the relationship between somatotroph adenomas and somatostatin analogs, and characteristics of plurihormonal adenomas.
引用
收藏
页码：51 / 56
页数：6
相关论文
共 19 条
[1]   The 2004 World Health Organization classification of pituitary tumors: What is new? [J].
Al-Shraim, M ;
Asa, SL .
ACTA NEUROPATHOLOGICA, 2006, 111 (01) :1-7
[2]   From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal [J].
Asa, S. L. ;
Casar-Borota, O. ;
Chanson, P. ;
Delgrange, E. ;
Earls, P. ;
Ezzat, S. ;
Grossman, A. ;
Ikeda, H. ;
Inoshita, N. ;
Karavitaki, N. ;
Korbonits, M. ;
Laws, E. R., Jr. ;
Lopes, M. B. ;
Maartens, N. ;
McCutcheon, I. E. ;
Mete, O. ;
Nishioka, H. ;
Raverot, G. ;
Roncaroli, F. ;
Saeger, W. ;
Syro, L. V. ;
Vasiljevic, A. ;
Villa, C. ;
Wierinckx, A. ;
Trouillas, J. .
ENDOCRINE-RELATED CANCER, 2017, 24 (04) :C5-C8
[3]   Molecular Determinants of Pituitary Cytodifferentiation [J].
Sylvia L. Asa ;
Shereen Ezzat .
Pituitary, 1999, 1 (3-4) :159-168
[4]  
DeLellis RA, 2004, WHO CLASSIFICATION T, P10
[5]   Clinical review: Diagnosis and management of pituitary carcinomas [J].
Kaltsas, GA ;
Nomikos, P ;
Kontogeorgos, G ;
Buchfelder, M ;
Grossman, AB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :3089-3099
[6]  
Kontogeorgos G., 2017, WHO CLASSIFICATION T, P39
[7]   Classification and pathology of pituitary tumors [J].
George Kontogeorgos .
Endocrine, 2005, 28 (1) :27-35
[8]   The new WHO classification of pituitary tumors: highlights and areas of controversy [J].
Laws, ER ;
Lopes, MBS .
ACTA NEUROPATHOLOGICA, 2006, 111 (01) :80-81
[9]  
LEVERATTO JM, 2017, WHO CLASSIFICATION T, P13
[10]   The 2017 World Health Organization classification of tumors of the pituitary gland: a summary [J].
Lopes, M. Beatriz S. .
ACTA NEUROPATHOLOGICA, 2017, 134 (04) :521-535
12